– Pivotal Phase 3 clinical trial reinforced efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) — — Acute treatment of migraine with ubrogepant compared with placebo led to significantly greater...
– Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort – All 12 patients in...
Partnering with Altoida, Inc. to Leverage Predictive Digital Biomarkers for Detection of Mild Cognitive Impairment due to Alzheimer’s Disease Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic...
The Trial will be conducted in the National Cancer Center Hospital of the National Cancer Center Japan. Image credit- shuttershock.com Cancer Intelligence Care Systems, Inc. (CICS) and STELLA PHARMA CORPORATION will commence a Phase I clinical trial of Boron Neutron...
It was a busy week for clinical trial announcements. Here’s a look. ASLAN Pharmaceuticals announced topline data from its TreeTopp (TREatmEnT OPPortunity with varlitinib in biliary tract cancer) trial in second-line biliary tract cancer (BTC). The drug failed to meet...
– Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019 – Phase 2 dose selection and expansion into Phase 2...
Email
Text